Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 272

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Open access
Kennedy, Nicholas A, Lin, Simeng, Goodhand, James R, Chanchlani, Neil, Hamilton, Benjamin, Bewshea, Claire, Nice, Rachel, Chee, Desmond, Cummings, JR Fraser, Fraser, Aileen, Irving, Peter M, Kamperidis, Nikolaos, Kok, Klaartje B, Lamb, Christopher Andrew, Macdonald, Jonathan, Mehta, Shameer, Pollok, Richard CG, Raine, Tim, Smith, Philip J, Verma, Ajay Mark, Jochum, Simon, McDonald, Timothy J, Sebastian, Shaji, Lees, Charlie W, Powell, Nick, Ahmad, Tariq · 2021 · Gut

Abstract

Objective: Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Design: Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared with a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin α4β7 monoclonal antibody. Our primary outcome was anti-SARS-CoV-2 spike (S) antibody concentrations, measured using the Elecsys anti-SARS-CoV-2 spike (S) antibody assay 3–10 weeks after vaccination, in patients without evidence of prior infection. Secondary outcomes were seroconversion rates (defined by a cut-off of 15 U/mL), and antibody responses following past infection or a second dose of the BNT162b2 vaccine. Results: Geometric mean (SD) anti-SARS-CoV-2 antibody concentrations were lower in patients treated with infliximab than vedolizumab, following BNT162b2 (6.0 U/mL (5.9) vs 28.8 U/mL (5.4) p<0.0001) and ChAdOx1 nCoV-19 (4.7 U/mL (4.9)) vs 13.8 U/mL (5.9) p<0.0001) vaccines. In our multivariable models, antibody concentrations were lower in infliximab-treated compared with vedolizumab-treated patients who received the BNT162b2 (fold change (FC) 0.29 (95% CI 0.21 to 0.40), p<0.0001) and ChAdOx1 nCoV-19 (FC 0.39 (95% CI 0.30 to 0.51), p<0.0001) vaccines. In both models, age ≥60 years, immunomodulator use, Crohn’s disease and smoking were associated with lower, while non-white ethnicity was associated with higher, anti-SARS-CoV-2 antibody concentrations. Seroconversion rates after a single dose of either vaccine were higher in patients with prior SARS-CoV-2 infection and after two doses of BNT162b2 vaccine. Conclusion: Infliximab is associated with attenuated immunogenicity to a single dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab. Trial registration number: ISRCTN45176516 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2021-324789

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 272

Metadata

Authors
Kennedy, N. A., Lin, S., Goodhand, J. R., Chanchlani, N., Hamilton, B., Bewshea, C., Nice, R., Chee, D., Cummings, J. F., Fraser, A., Irving, P. M., Kamperidis, N., Kok, K. B., Lamb, C. A., Macdonald, J., Mehta, S., Pollok, R. C., Raine, T., Smith, P. J., Verma, A. M., Jochum, S., McDonald, T. J., Sebastian, S., Lees, C. W., Powell, N., & Ahmad, T.
Venue
Gut
Publisher
BMJ
Published
2021-04-26
Volume
70
Issue
10
Pages
1884-1893
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3158750369
Cited by
272
References
30
FWCI
18.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. https://app.cochat.ai/papers/10.1136/gutjnl-2021-324789
The paper
Kennedy, N. A., Lin, S., Goodhand, J. R., Chanchlani, N., Hamilton, B., Bewshea, C., Nice, R., Chee, D., Cummings, J. F., Fraser, A., Irving, P. M., Kamperidis, N., Kok, K. B., Lamb, C. A., Macdonald, J., Mehta, S., Pollok, R. C., Raine, T., Smith, P. J., . . . Ahmad, T. (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. https://doi.org/10.1136/gutjnl-2021-324789

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.